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Abstract
 .Sphingosine, which is on the pathway of sphingomyelin degradation, activates phospholipase C PLC d 1 moderately. In
the liposome assay effect of sphingosine on PLC d 1 activity depends on KCl concentration. Stimulation of PLC d 1 by
sphingosine increased as the KCl concentration is increased from 0 to 100 mM, and then diminished with the increasing
KCl. In the liposome assay sphingosine diminishes inhibition of PLC d 1 by sphingomyelin. To determine the domain of
PLC d 1 which interacts with sphingosine active proteolytic fragments of PLC d 1 were generated by trypsin digestion of
the native enzyme. Sphingosine affects the activity of PLC d 1 fragment which lacked the amino-terminal domain first 60
.amino acids but not the active fragment that has cleaved the domain spanning the X and Y region of PLC d 1. These
observations indicate that for interaction of sphingosine with PLC d 1 intact domain that span regions of conservation,
designated as X and Y is necessary. When the activity of PLC d 1 was assayed with PIP in the erythrocyte membrane as2
substrate, sphingosine strongly inhibited PLC d 1. The other homolog of sphingosine 4-hydroxysphinganine phytosphingo-
.sine inhibited PLC d 1 to much lesser extent. The activity of PLC d 1 was inhibited by 68% and 22% in the presence of 20
mM sphingosine and phytosphingosine, respectively. This inhibition was completely abolished by deoxycholate at a
concentration of 1.5 mM. These observations suggest that sphingosine may regulate activity of PLC d 1 in the cell.
Keywords: Phospholipase C d 1; Sphingosine; Erythrocyte membrane
1. Introduction
Three major types of phosphoinositide-specific
 .phospholipase C PLC , called b , g and d , have
Abbreviations: PLC, phospholipase C; SM, sphingomyelin;
Sph, sphingosine; PC, phosphatidylcholine; PE, phos-
phatidylethanolamine; PIP , phosphatidylinositol-4,5-bisphos-2
phate; PIP, phosphatidylinositol-4-phosphate; TLL, total rat liver
lipids; IP , inositol-1,4,5-triphosphate; FGF, fibroblast growth3
factor; NGF, nerve growth factor; PDGF, platelet-derived growth
factor; RhoGAP, Rho-specific GTPase activating protein
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w xbeen characterized 1,2 . These different forms of
PLC all hydrolyse phosphatidylinositol 4,5-bisphos-
 .phate PIP . They are also capable of hydrolysing2
 .phosphatidylinositol 4-phosphate PIP and phos-
 .phatidylinositol PI , but the extent to which they do
so under physiological conditions is uncertain. The
purified isoforms of PLC are soluble, but in cell
homogenates substantial amounts are found in mem-
w xbrane-bound forms 3–6 . The different isoforms of
PLC are regulated differently. PLC g appears to be
regulated by tyrosine phosphorylation in response to
w xEGF, FGF, NGF and PDGF receptor occupancy 7 .
The phosphorylation of PLC g does not affect the
0005-2736r97r$17.00 Copyright q 1997 Elsevier Science B.V. All rights reserved.
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kinetic properties of the enzyme, but causes a redis-
tribution of the enzyme from cytosol to cell mem-
w xbrane 8,9 . Tyrosine phosphorylation of PLC g pro-
motes its association with actin components of the
w xcytoskeleton 10,11 . PLC b isozymes are activated
by the a and bg subunits of the heterotrimeric G
w xproteins 12–14 . The receptors that are known to
activate PLC b by a subunit of Gq are those for
bradykinin, angiotensin II, thromboxane A2, vaso-
w xpressin and acetylcholine 12 . The receptors for in-
terleukin-8 and m2 and m4 subtypes of muscarinic
acetylcholine receptor activate PLC b by bg sub-
w xunits of G proteins 12,15–17 . The activation mecha-
nism of PLC d isozymes is not known at the present
w xtime. Banno and colleagues 18 reported that throm-
bin-stimulated phophoinositide hydrolysis in Chinese
hamster ovary cells overexpressed PLC d 1 was de-
pendent on proteins G and calcium. Recently, Homma
and Emori reported that PLC d 1 binds to a novel
w xRhoGAP protein 19 . This may suggest that in regu-
lation of PLC d 1 may be involved the Rho signalling
pathway. Previously it has been reported that
sphingomyelin is a strong inhibitor of PLC d 1 and
that this enzyme binds strongly to phospholipids vesi-
w xcles containing PIP or sphingomyelin 20–22 .2
Turnover and net decline of SM have been observed
in response to extracellular signals, including 1 a ,
w x25-dihydroxyvitamin D 23 , tumor necrosis factor a3
w x w x w x24 , g-interferon 25 , interleukin-1 26,27 , arachi-
w x w xdonate 28 , and brefeldin A 29 . Recently Linardic
and Hannun reported that exposing U937 leukemia
cells to TNF-a results exclusively in hydrolysis of
sphingomyelin located within the inner leaflet of the
w xplasma membrane 30 . Hydrolysis of sphingomyelin
results in generation of ceramide which may be con-
w xverted to sphingosine by ceramidase 31 . Sphin-
gosine is a potent inhibitor of protein kinase C in
vitro and of cellular events dependent on this enzyme
w x32 . Many systems have been found to be affected
by sphingosine including inhibition of oxidative burst
in human neutrophils, the release of arachidonic acid,
PAF formation, expression of viral genes and cell
growth and differentiation in several cell types
w x32,33 . Previously it has been reported that sphingo-
sine moderately activates PLC d 1 in the absence of
w xspermine 20 . Here we showed that sphingosine
stimulates PLC d 1 in detergent and liposome assay.
For sphingosine interaction with PLC d 1, intact do-
main that span the regions of conservation named X
and Y is necessary. However, in assay with PIP2
located in erythrocyte membranes, sphingosine is a
strong inhibitor of PLC d 1 activity. We postulate
that in interaction of PLC d 1 with plasma mem-
branes besides PIP other phospholipids are involved2
and sphingosine competes with them for the same
binding site within the PLC d 1 molecule.
2. Materials and methods
Spermine, leupeptin, soybean trypsin inhibitor,
penicillin, adenine, sphingosine, phytosphingosine,
and crude phosphoinositide mixture were from
 .Sigma-Aldrich Sp. z o.o. Poznan, Poland . Pefabloc
 .SC, trypsin sequencing grade were from Boehringer
 .Mannhein GmbH Biochemica Mannhein, Germany .
w 3 x  . w32 x2- H Inositol-PI-4,5-P 4.8 Cirmmol and P or-2
thophosphoric acid were purchased from Du Pont
 .GmbH Dreieich, Germany . Unlabeled phos-
phatidylinositol, phosphatidylethanolamine, phos-
phatidylcholine and sphingomyelin were from Avanti
 .Polar Lipids, Inc. Birmingham, AL, USA .
Unlabeled PIP and PIP were purified from a2
crude phosphoinositide mixture by thin-layer chro-
matography according to the method of Jolles et. al.
w x34 . This method was also used for analytical separa-
tion of PIP and PIP. Phospholipid concentrations2
w xwere determined after perchloric acid digestion 35
w xby measuring orthophosphate 36 . Protein was deter-
w xmined by the method of Bradford 37 using bovine
serum albumin as standard, or by measuring the
absorbance at 280 nm.
PLC d 1 was prepared from rat liver as described
w xpreviously 38 . Purified enzyme reacts with rabbit
anti-PLC d 1 but not with anti-PLC d 3 nor anti-PLC
d 2 polyclonal antibodies.
2.1. Proteolysis with trypsin
 .Purified rat liver PLC d 1 30–50 mg was incu-
bated with trypsin at a molar ratio of PLC d 1:tryp-
.sin of 25:1 for different periods of time in 50 mM
 .Hepes-NaOH buffer pH 7.2 , 5 mM CaCl , 5 mM2
DTT, 100 mM NaCl, 2.4 mM sodium deoxycholate
at 248C. The reaction was stopped by the addition of
soybean trypsin inhibitor. The active fragments of
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PLC d 1 were purified on a Mono S FPLC column as
w xdescribed 38 .
2.2. Sequencing
Purified active fragments of PLC d 1 have been
 .subjected to SDSrPAGE 10% according to
w xLaemmli 39 and electroblotted onto Immobilion-P
 .Millipore . After blotting, the membrane was stained
with Coomassie Brilliant Blue, destained with 50%
methanol, 15% acetic acid, and washed with water.
The excised bands were subjected to sequence analy-
 . TMsis on Applied Biosystem ABI Pulsed Liquid
Protein sequencer.
2.3. Preparation of labeled erythrocyte inside-out
˝esicles
Human erythrocytes were prepared as described
previously from blood withdrawn from healthy vol-
w xunteers 40 . Cells for labeling were resuspended in
 .150 mM NaCl, 5 mM sodium phosphate pH 8.0 ,
0.5 mM EGTA, 10 mM glucose, 1 mM adenine, 5
mM inosine, 100 mg streptomycinrml, 100 units
penicillinrml and incubated in the presence of 32PO4
 . w x20 mCirml cells for 20 h 41 . Incubation was
terminated by addition of ice-cold sodium phosphate
 .pH 8.0 , 150 mM NaCl, 0.5 mM EGTA, sedimented
and washed twice in the same buffer. White ghosts
were prepared from 32P-pre-labeled cells as described
w x42 . The ‘inside-out’ vesicles were prepared by incu-
bation of white ghosts in 30 vols. 0.1 mM EGTA pH
.8.5 at 378C for 30 min. Resultant vesicles were
depleted of spectrin and actin. Removal of remaining
peripheral proteins was achieved by incubation of
w xinside-out vesicles at alkaline pH as described 40,43 .
The alkaline-stripped vesicles were subsequently used
for experiments and in the text are referred to as
erythrocyte vesicles.
To measure changes in phospholipid content re-
sulting from the different treatments described above,
control and prepared ghost, i.e., inside-out vesicles or
stripped vesicles were submitted to an acidic lipid
w xextraction as described 41 . The phospholipid separa-
tion was performed by thin-layer chromatography
w xaccording to the method of Jolles et al. 34 . Phospho-
lipids were located on chromatography plate by stain-
ing in iodine vapor. Spots corresponding to identified
phospholipids were scrapped and radioactivity and
phospholipid concentration was measured.
2.4. Assays for PLC d1
PLC d 1 activity was assayed as described in
w xdetails previously 20 . The reaction mixture for de-
w 3 xtergent assay contained 17 nmolrml 2- H inositol-
 .labeled phosphatidylinositol-4,5-bisphosphate PIP2
 .0.005 mCirnmol , 2.4 mM sodium deoxycholate,
180 mM NaCl, 100 mM CaCl , 100 mM EGTA, 502
 .mM HEPES-NaOH buffer pH 7.2 . The reaction was
started by adding PLC d 1 and was run in a final
volume of 0.1 ml at 378C for 1 min. In this reaction
mixture, the concentration of free Ca2q was 2.2 mM
w xas determined by the arsenazo method 44 .
The reaction mixture for the liposome assay con-
w 3 xtained 25 nmolrml 2- H inositol-labeled phos-
 . phatidylinositol-4,5-bisphosphate PIP 0.012
.mCirnmol , 200 nmolrml of 9:1 mixture of phos-
 .phatidylethanolamine PE and phosphatidylcholine
 .PC and other phospholipids as indicated in the
figure legends, 180 mM NaCl, 100 mM CaCl , 1002
mM EGTA, and 50 mM Hepes-NaOH buffer pH
.7.2 . The concentration of free calcium was 2.2 mM.
The reaction was started by adding enzyme and was
run in a final volume of 0.1 ml at 378C for 1 min.
The reaction mixture for the erythrocyte vesicles
assay contained 80 nmolrml erythrocyte vesicle
32  .phospholipids labeled with PO 0.002 mCirnmol ,4
120 mM KCl, 60 mM NaCl, 100 mM CaCl , 1002
mM EGTA, 20 mM leupeptin, 0.2 mM Pefabloc SC
 .and 50 mM HEPES-NaOH buffer pH 7.2 . The
concentration of free calcium was 2.2 mM. The
reaction was started by adding enzyme and was run
in a final volume of 0.1 ml at 378C for 5 min.
In all assays, the reaction was stopped by adding
0.1 ml of 1.2 N HCl, the mixture was vortexed, 0.5
 .ml chloroform-methanol 2:1 was added, and the
mixture was vortexed again. The aqueous layer was
separated, and an aliquot was taken for counting.
Assay conditions were chosen so that the reaction
rate was proportional to time and enzyme concentra-
tion. In all assays neither the substrate nor the in-
hibitor was in true solution. For this reason we prefer
to quote their concentrations as nmolrml. If substrate
and inhibitor were in true solution, nmolrml would
become mM.
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3. Results
Investigating the phospholipid dependence of PLC
d 1, we used detergent and liposome assay. In the
detergent assay substrate and examined phospholipid
are present in the mixed deoxycholate micelles. The
advantage of this assay is that it allows measurement
of the activity of the enzyme that lacks the ability to
bind to lipid membrane. In addition the number of
phospholipid molecules per micelle can be systemati-
cally varied in a defined physical environment, the
mixed micelle. On the other hand, the liposome assay
where phospholipids are located in the bilayer vesi-
cles provides a surface resembling the plasma mem-
brane; thus, a more physiological environment for
interaction of phospholipid and the enzyme. The
regulation of PLC d 1 in vitro critically depends
2q w xon phospholipid, polyamines, and Ca 20,45,46 .
Sphingomyelin is the most effective of the phospho-
w xlipids tested for its ability to inhibit PLC d 1 20 .
Sphingosine, which is on the pathway of SM degra-
dation, activates PLC d 1 moderately. The other ho-
molog of sphingosine 4-hydroxysphinganine phyto-
. sphingosine activates PLC d 1 to a lesser extent Fig.
.1 . Investigating the effect of sphingosine on PLC d 1
activity, we found that sphingosine in 0–50 mM
range activates PLC d 1 in all assays employed.
Fig. 1. Effect of sphingosine, phytosphingosine and spermine on
the activity of PLC d 1. The detergent assay was used as de-
scribed in Section 2. One hundred percent activity was 1.36
nmolrmlrmin. The average standard deviation for all points was
 ."3.7% ns4 .
Fig. 2. Effect of sphingosine on PLC d 1 activity in different
assays. The reaction mixture for each assay was as described in
Section 2. DOC, the sodium deoxycholate assay. V , thePIP2
 .liposome assay, the vesicles consisted PIP 25 nmolrml only.2
V , liposome assay, the vesicles consisted 200 nmolrml totalTLL
liver lipids, 25 nmolrml PIP . V , liposome assay, the2 PEqPC
 .vesicles consisted 200 nmolrml PEqPC 9:1 and 25 nmolrml
 .  .PIP . 100% represents activities of 0.97 DOC , 0.82 V ,2 PIP2
 .  .0.93 V and 0.75 V nmol PIP hydrolyzedrmlrmin.TLL PEqPC 2
The average standard deviation for all points was; DOC, "3.9%
 .  .  .ns5 ; V , "5.4% ns3 ; V , "6.7% ns4 , V ,PIP2 TLL PEqPC
 ."7.5% ns3 .
However, in the liposome assay activation of PLC
d 1 by sphingosine declined when sphingosine con-
centration increased above 50 mM molar ratio phos-
.  .pholipids : sphingosine 4:1 Fig. 2 . The simplest
explanation of this observation could be the substrate
redistribution between inner and outer leaflet of the
phospholipid bilayer caused by sphingosine. In order
to examine such a possibility we have allowed the
 .liposome assay to continue. The liposome TLL
assay leveled off when about 38% of the 25 nmolrml
of PIP was hydrolyzed either in the presence or2
absence of sphingosine at concentrations of 50–200
mM. Upon adding 2.4 mM deoxycholate to the reac-
tion mixture, the remainder of the substrate was
hydrolyzed to within 98–99%. Effect of 50 mM
sphingosine on accessibility and time course of PIP2
hydrolysis in TLL liposome assay is shown in Fig. 3.
Based on the results obtained, we conclude that the
distribution of PIP between the two membrane2
leaflets of TLL liposomes was not affected by sphin-
 .gosine 50–200 mM . The same effect of sphingosine
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Fig. 3. Effect of sphingosine on the distribution of PIP in TLL2
liposomes. The reaction mixture was as described in Section 2.
The vesicles consisted 200 nmolrml of total liver lipids and 25
nmolrml PIP . The concentration of sphingosine was 502
 .  .nmolrml e , 200 nmolrml n . In the control sphingosine was
 .omitted o . At 35 min 50% of the reaction mixture was with-
drawn and to this sample deoxycholate was added to concentra-
 .tion of 2.4 mM closed symbols . Each point represents the mean
"S.D. of triplicate determinations.
was observed in assay with PEqPC liposomes.
However, the distribution of PIP between the two2
membrane leaflets of PEqPC liposomes was differ-
ent from that of TLL liposomes. In PEqPC lipo-
 .somes 65% of PIP faces outward not showed . Data2
from experiments with detergent and liposome assay
suggested that the nature of sphingosine up to 50
.mM interaction with PLC d 1 is the same in both
kinds of assay. Therefore in our experiments we
chose to use sphingosine at concentrations up to 50
mM that is close to concentration of this agent in
w xliving cells 47–49 . In interaction of sphingosine
with PLC d 1, ionic as well as hydrophobic forces
may be involved. In the liposome assay, the activity
of PLC d 1 increased with the increasing KCl concen-
 .tration Fig. 4 . These results may indicate that for
interaction of the enzyme with PIP located in the2
phospholipid membrane hydrophobic forces are in-
volved. Increasing ionic strength results in a weaken-
ing of the electrostatic intermolecular interactions,
allowing hydrophobic interactions to take place. The
highest activation of PLC d 1 by sphingosine occurs
at 50 mM KCl and it diminishes with increasing KCl
Fig. 4. Effect of KCl concentration on PLC d 1 activity in the
 .liposome PEqPC assay in the presence of sphingosine. The
reaction mixture was as described in Section 2. The vesicles
 .consisted 200 nmolrml of PEqPC 9:1 and 25 nmolrml PIP .2
 .The sphingosine Sph concentration was 50 nmolrml. Each
 .point represents the mean "S.D. ns3
 .Fig. 4 . Increase in ionic strength of the reaction
medium from 0.08 to 0.4 M caused a decrease in
activation of PLC d 1 by sphingosine from 200% to
0%. These results may indicate that in interaction of
PLC d 1 with sphingosine electrostatic forces are
involved and that PIP and sphingosine interact with2
different protein domains of the enzyme. This as-
sumption was confirmed by the experiments with the
Fig. 5. Limited proteolysis of rat liver PLC d 1 by trypsin. Rat
liver PLC d 1 was incubated with trypsin as described in Section
2. The active fragments were purified by ion exchange chro-
matography and subjected to SDS-PAGE on 12% gel. Intact rat
 .liver PLC d 1 lane 1 ; purified active fragment of PLC d 1
 .  .obtained by 15 min lane 2 and 1 h lane 3 incubation with
trypsin.
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Fig. 6. The effect of sphingosine on the activity of PLC d1 and
its proteolytic fragments. The detergent assay was used as de-
 .scribed in Section 2. Activity of the native PLC d1 o , the 77
 .  .kDa fragment e , the 70 kDa fragment n . One hundred
percent activity for native PLC d1 was 1.36 nmolrmlrmin, for
77 kDa fragment was 0.2 nmolrmlrmin, for 70 kDa fragment
was 0.18 nmolrmlrmin. The results are mean values "S.D.
 .ns3 .
active fragments of PLC d 1 generated by proteolysis
with trypsin. Under employed conditions we have
obtained two kinds of PLC d 1 active fragment.
Limited proteolysis of PLC d 1 with trypsin for 15
min resulted in the generation of a catalytically active
 .77 kDa fragment Fig. 5 . Sequence analysis reveals
that trypsin digestion of PLC d 1 resulted in the
generation of 77 kDa fragment, which lacked the first
60 amino acids. The N-terminal part of PLC d 1
within first 135 amino acids contains a pleckstrin
 .homology PH domain, which is required for mem-
w x w xbrane attachment 50,51 and PIP 52 and PI bind-2 3
w xing 53 . It was reported that 77 kDa fragment of PLC
d 1 does not bind to phospholipid vesicles containing
w xPIP 50,53 , thus is inactive in liposome assay. In2
detergent assay the effect of sphingosine on intact
 .PLC d 1 and 77 kDa fragment was the same Fig. 6 .
This may indicate that interaction of sphingosine with
PH domain of PLC d 1 is not necessary for activation
of the enzyme. Previously it was reported that pro-
longed digestion of PLC d 1 with trypsin generates
w xsmaller active fragments of the enzyme 50,54,55 .
After 1 h digestion of PLC d 1 with trypsin and
purification on Mono S cation exchange column, we
obtained a 70 kDa catalytically active product which
on SDS-PAGE separates into 40 kDa and 30 kDa
 .polypeptides Fig. 5 . Sequencing of the generated
polypeptides confirmed sequences reported previ-
ously and showed that the 40 kDa polypeptide con-
tains the aminoterminal part of region X and the 30
kDa polypeptide corresponded to part of the spanning
w xregion and complete region Y 54 . Data from our
 .experiments with 70 kDa PLC d 1 not shown are
very similar to those obtained by other in respect to
activation by calcium, rate of PIP hydrolysis in2
detergent assay and lack of binding to phospholipid
w xvesicles 50,54 . As can be seen in Fig. 6 sphingosine
does not activate the 70 kDa PLC d 1 in detergent
assay. This may indicate that in interaction of sphin-
gosine with PLC d 1, intact region spanning X and Y
is necessary.
Because sphingosine is an metabolite of sphingo-
myelin we tested the effect of sphingosine on inhibi-
tion of PLC d 1 caused by SM. Fig. 7 illustrates the
effect of sphingosine and sphingomyelin on PLC d 1
 .activity measured in liposome TLL assay. The pres-
ence of 50 mM sphingosine protects PLC d 1 against
inhibition caused by 50 mM sphingomyelin.
In the action of PLC d 1 on the substrate localized
in cell membrane two main steps can be distin-
guished, i.e., binding to the membrane surface and
Fig. 7. Effect of sphingosine on the inhibition of PLC d 1 by
sphingomyelin in the liposome assay. The reaction mixture was
as described in Section 2. The vesicles consisted 200 nmolrml of
 .total liver lipids TLL and 25 nmormL PIP . A, TLL liposomes2
 .  .only. B, sphingomyelin SM 50 nmolrml, sphingosine Sph 50
 .nmolrml. C, sphingomyelin SM 100 nmolrml, sphingosine
 .  .Sph 50 nmolrml. The results are mean values "S.D. ns4
( )A. Matecki, T. PawelczykrBiochimica et Biophysica Acta 1325 1997 287–296 293
interaction with the substrate. Beside lipid composi-
tion of the membrane, both steps of PLC d 1 action
depend on the physical state of the membrane. Previ-
w xously it was reported that the activity of PLC d 1 56
w xand other PLC’s 57,58 depends on surface pressure
and the electrostatic surface potential of lipid mem-
brane. Binding of several other proteins to phospho-
lipid membrane decreases as the surface pressure
w xincreases 59–61 . The surface stress of lipid vesicles
depends on lipid composition and the curvature of the
membrane. In an attempt to set the assay of PLC d 1
in a more physiological context in terms of
.physical-chemical properties of the membrane , we
tested the effect of sphingosine in assay with erythro-
cyte membranes. We chose to use erythrocyte mem-
brane because is the best characterized and simplest
cell membrane widely used by other investigators. In
w32 xerythrocytes incubated with P Pi, the only labeled
lipids are polyphosphoinositides and phosphatidic acid
w x62 . This is because in these simple cells there is no
 .synthesis of phosphatidylinositol PI , but only a
turnover of the 4-phosphate of PIP and of the 4- and
5-phosphate groups of PIP by specific kinases and2
phosphatases and synthesis of PA from diacylglyc-
Fig. 8. Inhibition of PLC d 1 by sphingosine in the erythrocyte
membrane assay. The reaction mixture was as described in
Section 2. The reaction mixture contained 100 nmolrml of
 .erythrocyte membrane phospholipids 1300 cpmrnmol and the
effector at indicated concentrations. Total PIP q PIP was 96202
cpmrassay. 100% represents an activity which releases to H O2
phase 925 cpmr5 min. The average standard deviation for all
 .points was; sphingosine, "10.6% ns4 ; phytosphingosine,
 .  ."9.2% ns3 ; palmitoyl-L-carnitine, "7.3% ns3 .
Fig. 9. Effect of sodium deoxycholate on the activity of PLC d 1
in the erythrocyte membrane assay. The reaction mixture was as
described in Section 2. The reaction mixture contained 100
nmolrml of erythrocyte membrane phospholipids 1400
.cpmrnmol , sodium deoxycholate at indicated concentrations
and 50 nmolrml of sphingosine where indicated. Total PIP q2
PIP was 10 500 cpmrassay. 100% represents an activity which
releases to H O phase 565 cpmr5 min. The results are mean2
 .values "S.D. ns3 .
w xerol by a specific kinase 63 . We used alkali-stripped
w32 xinside-out vesicles containing labeled P phos-
pholipids. We found that erythrocyte membrane assay
leveled off when about 70–75% of total lipid 32P was
 .liberated as a water soluble compounds not showed .
This accounted for 92–97% of both PIP and PIP .2
The remaining 25–30% radioactivity was phospha-
 w x.tidic acid see Ref. 63 . Assay conditions were
chosen so that the 10–15% of the PIPqPIP in the2
membranes were hydrolyzed. The data shown in Fig.
8 demonstrate that sphingosine in assay with erythro-
cyte membranes strongly inhibits activity of PLC d 1.
 .Phytosphingosine 4-hydroxysphinganine , which is a
homolog of sphingosine, inhibits PLC d 1 to much
lesser extent. The concentrations for 50% inhibition
by sphingosine and phytosphingosine were 15 and 50
nmolrml, respectively. Palmitoyl carnitine at concen-
trations up to 100 nmolrml did not inhibit PLC d 1
under conditions where sphingosine inhibited strongly
 .Fig. 8 . Carnitine esters, and to the some extent
sphingosine, have detergent-like properties. The ob-
servation that palmitoyl carnitine did not affect PLC
d 1 activity indicates that the inhibition of the enzyme
by sphingosine in the erythrocyte membrane assay is
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not due to a non-specific detergent effect. On the
other hand, in the presence of increasing concentra-
tions of sodium deoxycholate, the inhibition of PLC
 .d 1 by sphingosine declined Fig. 9 . Inhibition of
PLC d 1 by sphingosine was completely abolished by
1.5 mM deoxycholate.
4. Discussion
The inhibitory effect of sphingomyelin on PLC d 1
w xactivity was described previously 20 . In binding
experiments PLC d 1 shows a high degree of speci-
w xficity for PIP and sphingomyelin 21,22 . It has been2
proposed that, in vivo, sphingomyelin acts as an
inhibitor of PLC d 1, which enables the enzyme to be
w xregulated by activation 20 . A number of extracellu-
lar signaling molecules can induce turnover and tran-
w xsient decline of sphingomyelin 64,65 , possibly lead-
ing to a partial relief of PLC d 1 inhibition. Here, we
showed that sphingosine, which is on the pathway of
sphingomyelin degradation, activates PLC d 1 moder-
ately in the liposome and detergent assay Figs. 1 and
.2 . However, in the assay with erythrocyte mem-
branes sphingosine becomes a strong inhibitor of the
 .enzyme Fig. 8 . The stimulatory effect of sphingo-
sine on PLC d 1 activity in the detergent assay and
the assay with substrate as a small liposome formed
 .from PIP Fig. 2 indicates that sphingosine does not2
interfere with binding of the enzyme to its substrate.
The weak activation of PLC d 1 observed in both
assays seems to be the effect of structural changes of
the enzyme induced by sphingosine binding. In-
creased ionic strength of the reaction medium 0.04–
.0.2 M in the liposome assay resulted in activation of
PLC d 1 to the same extent as 50 nmolrml sphingo-
 .sine Fig. 4 . The structural changes of PLC d 1
induced by binding of sphingosine may affect interac-
tion of the enzyme with other phospholipids. In the
assay with liposome composed of PEqPC and lipo-
somes containing TLL sphingosine at concentration
higher than 50 nmolrml does not activate PLC d 1,
but instead becomes an inhibitor of the enzyme Fig.
.2 . Thus, diminution of the sphingomyelin inhibition
of PLC d 1 observed in the presence of sphingosine
in the liposome assay may be explained by the
decreased binding of SM to the enzyme resulting
 .from changes in the protein structure Fig. 5 . Results
obtained from experiments with the active fragments
of PLC d 1 indicate that for interaction of sphingo-
sine with the enzyme, intact regions that span domain
 .X and Y is necessary Fig. 6 . In rat PLC d 1 this
spanning region contains 49 residues with a high
w xpercentage of acidic amino acids 66 . Between
residues 450 and 472, seven glutamic acids and three
aspartic acids are located. It might be assumed that
interaction of polar lipids especially with positively
charged head group takes place within this region of
PLC d 1. The exact mechanism by which sphingosine
inhibits PLC d 1 in the assay with erythrocyte mem-
branes remains undefined. The possibility exists that
sphingosine inhibits activity of PLC d 1 by competi-
tion in interaction of the enzyme with the positively
charged lipids located in the cell membrane. Alterna-
tively, it might be assumed that sphingosine is in-
volved in the generation of binding sites within ery-
throcyte membrane which exclude the enzyme from
the substrate. The addition of the deoxycholate pre-
vents such structures from occurring and restores the
 .PLC d 1 activity Fig. 9 . The presented results are
suggestive of sphingosine being the physiological
inhibitor of PLC d 1 if it is assumed that the experi-
ments with erythrocyte membranes resemble in vivo
conditions.
Agonist-stimulated breakdown of sphingomyelin
results in ceramide generation which may be con-
verted to sphingosine by the action of neutral or acid
w xceramidase 64,65,67 . Assuming that, under physio-
logical conditions, PLC d 1 is bound to sphingo-
myelin in cellular membranes in an inactive form,
then it may be speculated that hydrolysis of SM
should result in activation of PLC d 1, but vitamin D3
or TNF-a-stimulated hydrolysis of SM did not induce
w xaccumulation of DAG or IP 69,70 . The lack of3
expected alteration in phosphoinositide breakdown
under declined level of SM may possibly be ex-
plained by an inhibitory effect of sphingosine on PLC
d 1 orrand by involvement of other regulatory factors
substantial for controlling this enzyme activity. Wil-
w xson and colleagues 47 demonstrated that sphin-
gomyelinase-generated sphingosine is regulated by
external effectors and that the levels of free sphingo-
sine in the human neutrophils cells can reach 7 nmol
w xper gram of wet tissue 48 . On the other hand it has
been reported that no increase in sphingosine could
 .be detected in response to the action of 1,25- OH D2 3
( )A. Matecki, T. PawelczykrBiochimica et Biophysica Acta 1325 1997 287–296 295
w xon HL-60 cells 71 . In human A431 epidermoid
carcinoma cells, the addition of 0.1–1 mM sphingo-
sine to the incubation medium resulted in an in-
creased cellular ceramide level while the sphingosine
w xlevel was not raised 72 . Although, at sphingosine
levels higher than 1 mM in the incubation medium
the cellular level of ceramide did not increase further,
while intracellular sphingosine was extremely ele-
w xvated 72 . Reported cellular sphingosine content var-
ied depending on cell type and quantitation method.
The sphingosine content of rodent liver is 7–14
w xnmolrg fresh wt 33,48,49 . Half of this is bound to
the plasma membrane fraction. Incubation of isolated
plasma membrane results in about a 3-fold rise in
w xmembrane-bound sphingosine 68 . Granulocytes con-
w xtain about 16 nmol sphingosinerml packed cells 47 .
Assuming that 50% of the packed cell volume is
intracellular water, this yields a concentration of about
32 nmolrml, which is at the high end of sphingosine
concentrations. This is about two times greater than
the concentration for 50% inhibition of PLC d 1 by
sphingosine in the erythrocyte membrane assay.
Whatever the precise mechanism, our results raise
the important question of whether cellular sphingo-
sine, formed by degradation of sphingolipids acts to
regulate the PLC d 1 activity. However, further ex-
periments are required to define the mechanism by
which sphingosine interacts with PLC d 1 acting on
plasma membranes.
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